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Abstract
Introduction: The ability to degrade neutrophil extracellular traps (NETs) is reduced in a subset of patients with
systemic lupus erythematosus (SLE). NETs consist of chromatin covered with antimicrobial enzymes and are
normally degraded by DNase-I, an enzyme which is known to have reduced activity in SLE. Decreased ability to
degrade NETs is associated with disease activity. In the current study we investigated how the ability of serum
from SLE patients to degrade NETs varies during the course of SLE as well as what impact this may have for the
clinical phenotype of SLE.
Methods: Serum from 69 patients with SLE, included in a prospective study, was taken every 60 days for a median
of 784 days. The ability of serum to degrade NETs was determined and associated with clinical parameters
occurring before and at the time of sampling, as well as after sampling by using conditional logistic regression.
Results: As many as 41% of all patients in the study showed decreased ability to degrade NETs at least once, but
with a median of 20% of all time points. Decreased degradation was associated with manifestations of
glomerulonephritis as well as low complement levels and elevated levels of antibodies directed against histones
and DNA. Furthermore, the odds ratio for the patient to develop alopecia and fever after an episode of decreased
NETs degradation was increased by four to five times compared to normal.
Conclusions: Decreased degradation of NETs is associated with clinical manifestations in SLE and may contribute
to disease pathogenesis. Potential therapeutics restoring the ability to degrade NETs could be beneficial for certain
patients with SLE.
Keywords: Systemic lupus erythematosus, neutrophil extracellular traps, degradation, glomerulonephritis,
prospective study
Introduction
The autoimmune disease systemic lupus erythematosus
(SLE) is a complex and heterogeneous disease with the
patients displaying a variety of symptoms ranging from
glomerulonephritis to skin rashes and chronic fatigue.
A common feature of SLE is the generation of anti-
nuclear antibodies. It has been hypothesized that SLE
evolves from the inefficient or improper clearance and
degradation of dying cells [1-4]. Numerous genes have
been associated with the disease, spanning from immune
modulatory genes to complement factors [5], all crucial to
ensure a proper immune response and efficient clearance
of apoptotic and necrotic cells. In 2004, a new potential
antigen source in SLE was discovered with the description
of neutrophil extracellular traps (NETs) [6]. NETs consist
of chromatin and antimicrobial enzymes that are released
from neutrophils as a “last-resort” defense to trap and kill
pathogens. It was subsequently shown in two independent
studies that NETs are efficiently degraded in serum from
healthy controls, whereas this ability is reduced in a sub-
population of SLE patients [7,8]. The patients with
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decreased ability to degrade NETs suffered from a severe
form of SLE with glomerulonephritis and additionally
exhibited autoantibodies that recognized NETs. Numerous
recent reports further show involvement of NETs in SLE.
This spans from how NETs are more easily formed by
neutrophils isolated from SLE patients, potentially through
elevated interferon-a levels or the presence of activating
antibodies in these patients to how non-degradable com-
plexes of chromatin and antimicrobial peptides are found
in SLE sera [9]. Together, this all could contribute to the
tissue damage in SLE [10]. It has long been known that
SLE patients display a decreased ability to degrade DNA
[11] and there are many theories why this is the case.
DNase-I is the enzyme responsible for degradation of
NETs and it is inhibited by globular actin. Actin may be
released by platelets, and dying cells during inflammation
[12] and has also been shown to prevent excessive chro-
matin degradation in apoptotic and necrotic cells [13].
Further, autoantibodies against DNA could shield the
DNA from DNase-I and have additionally been described
to cross react directly with the enzyme potentially leading
to inhibition [14]. We also showed that C1q binds to
NETs and prevents degradation [8], indicating formation
of non-degradable complexes on NETs consisting of auto-
antibodies and complement. Interestingly, in our previous
study we observed that the decreased ability of serum
from SLE patients to degrade NETs is mostly not perma-
nent but changes between time points with different dis-
ease activity [8]. To thoroughly determine the extent of
this phenomenon, we used serum samples from a prospec-
tive study where 69 patients with SLE were followed for up
to five years with samples taken approximately every two
months. At each sampling, we measured the ability of
patient serum to degrade NETs. Clinical manifestations,
laboratory variables and treatments were registered at all
time-points in the patients and these variables were used
to determine temporal associations with decreased ability
to degrade NETs. We identified a number of distinct clini-
cal manifestations and laboratory variables that preceded
the time-point of decreased NET degradation and some
that appeared at the same time-point as well as after the
time-point of decreased NET degradation.
Materials and methods
Patients and sample preparation
Sixty nine patients (6 males and 63 females) with a
majority of Caucasian origin, except for two with Asian
and one of Hispanic origin, with a median age of 39
(range 18 to 76) with established SLE, fulfilling at least
four or more American College of Rheumatology (ACR)
1982 classification criteria for SLE [15] were recruited to
this prospective study at the Department of Rheumatol-
ogy, Skåne University Hospital in Lund (Sweden). The
distribution of ACR classification criteria for SLE of the
patients is described in Table 1. The overall aims of the
prospective follow-up program were partly to improve
care by close monitoring of SLE-patients at risk of com-
plications and partly to identify risk factors, clinical and
laboratory variables, for disease exacerbations. Disease
activity was recorded at every visit using the SLE Dis-
ease Activity Index 2000 (SLEDAI-2K) [16] together
with infections and other clinically relevant information.
Visits were scheduled every two months with a range of
46 to 74 days, depending on disease activity. The med-
ian study duration for the patients was 784 days (mean
921 days) with a range of 139 to 1,792 days correspond-
ing to a median of 14 (2 to 43) visits. Only visits within
46 to 74 days were used for temporal associations. Sera
from 77 healthy volunteers (15 males and 62 females)
with a median age of 42 (range 19 to 77) were used as
controls. All patients and healthy controls gave informed
consent to participate in the study, which was approved
by the local ethics committee (Lund University) accord-
ing to the Helsinki declaration.
Isolation of neutrophils
Neutrophils were isolated from healthy volunteers accord-
ing to a previously published method [17]. Briefly, blood
from a healthy volunteer was separated by centrifugation
on a Histopaque 1119 column (Sigma-Aldrich, St Louise,
MO, USA), the granulocyte-rich fraction was isolated,
washed and neutrophils were isolated by centrifugation on
a Percoll gradient (85 to 65%) (GE Healthcare Biosciences,
Uppsala, Sweden) and isolated from the intersection of the
75% and 70% layers, washed and resuspended in RPMI
with 10 mM Hepes at 1 × 106 cells/ml. Purity of neutro-
phils (>80%) was determined by forward-side scatter ana-
lysis in combination with surface marker expression
defined as CD14low/CD15+/CD16+ by PE-labeled anti-
CD14 (BD), FITC-labeled anti-CD15 and APC-labeled
Table 1 ACR classification criteria of patients included in
study
ACR classification criteria Patient
number (%)
Malar rash 46 (67%)
Discoid rash 18 (26%)
Photosensitivity 42 (61%)




Neurological disorder 3 (4%)
Hematological disorder 38 (55%)
Immunological disorder 53 (77%)
Anti-nuclear antibodies 69 (100%)
Patient characteristics according to ACR classification criteria. ACR, American
College of Rheumatology
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anti-CD16 (both from Immunotools, Friesoythe, Ger-
many) in a CyFlow Space (Partec, Münster, Germany)
Generation and degradation of NETs
Freshly isolated neutrophils from healthy volunteers,
50,000/sample, were seeded onto a 96-well flat bottom
plate (Nunc, Thermo Fisher Scientific Inc, Waltham,
MA, USA) with 20 nM PMA (Sigma-Aldrich) for 4 h at
37°C and 5% CO2 to generate NETs. After incubation,
cell medium was removed and 10% patient sera, control
sera or sera with 5 to 320 μg/ml hydroxychloroquine
(Sigma-Aldrich) in 10 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 10 mM MgCl2 and 2 mM CaCl2 were added to
NETs and incubated for 60 minutes at 37°C. During this
time, degraded NETs were released into solution. Aliquot
of the solution was then transferred to PBS with a final
concentration of 2 mM EDTA to stop further degradation
and DNA content was quantified using picoGreen (Invi-
trogen, Grand Island, NY,) according to the manufac-
turer’s instructions. As an internal control, pooled normal
human serum was used and all samples were compared to
the mean of the internal controls for each individual
experiment. All samples were measured twice, first in
duplicates followed by once in singlets and the mean of
the two measurements was used for analysis.
Clinical laboratory assays
Routine laboratory testing at Department of Clinical
Immunology (Lund University Hospital, Lund, Sweden)
was used to determine levels of hemoglobin, white blood
cell count, neutrophil granulocytes, platelets, and levels of
anti-DNA (Crithidia luciliae immunofluorescence test)
and anti-cardiolipin titers as well as C-reactive protein
(CRP), creatinine, C1q, C3 and C4. Titers of anti-histone
antibodies were determined as previously described [18].
Reference values and medications
For the following variables, reference values used in clini-
cal routine were applied to construct categorized variables,
anti-cardiolipin >20 U/mL, low hemoglobin <120 g/L, low
serum creatinine is based on individual reference values
according to Gault and colleagues [19], low C1q <77% of
normal serum pool, low C3 <0.77 g/L, low C4 <0.12 g/L.
For cell counts the following values were used: leukopenia
<3 × 106 cells/ml, neutropenia <1.5 × 106 cells/ml and
lymphopenia <1.5 × 106 cells/ml. For medications, high
corticosteroid dosage was defined as dosages above
20 mg/day of prednisone and use of immunosuppressants
include: cyclophosphamide, mycophenolate mofetil,
azathioprine, cyclosporine A and methotrexate.
Statistical analysis
To determine statistical significance of difference for
continuous data among three groups or more, the
Kruskal-Wallis test was used followed by a post-test
using Dunn’s method for comparisons with control. To
determine significant differences for nominal data
between two groups the c2 test was used. All analyses
were carried out using JMP 7 and 9 (SAS Institute,
Cary, NC, USA). Association of clinical parameters with
a decreased ability to degrade NETs was determined
using conditional logistic regression with patient as
strata variable to handle repeated measurements within
subject, on SAS system 9.3 (SAS).
Results
Serum samples of SLE patients were taken every two
months for a median of 784 days (mean 921 days). The
duration of time for which each patient was included in
the study is displayed in Figure 1A. The disease activity
as measured by SLEDAI-2K scores, recorded from the
patients at each time point, improved significantly after
two years from the study inclusion (Figure 1B).
The presence of auto antigens, such as NETs, in SLE
fuels the inflammation contributing to the disease.
Therefore, we measured the ability of the patient’s sera
to degrade NETs at each time point of serum collection
throughout the study. To determine the normal range
of the ability to degrade NETs, sera from 77 healthy
volunteers were used (Figure 2A). A cut-off was set as
previously described [8] to three standard deviations
below the mean NET-degradation of the controls and
thus defined “normal” and “decreased” ability to degrade
NETs. The NET-degrading abilities were subsequently
measured in all patient samples and displayed over time,
starting at study inclusion (Figure 2B). From all measure-
ments recorded, a significant (P = 0.02) improvement
was observed in the third year after study inclusion (data
not shown), but varied highly for individual patients. To
quantify how common an episode with decreased ability
to degrade NETs is, the number of SLE patients whose
sera never showed decreased NET degradation was com-
pared with sera that showed decreased degradation at
least once. We observed that 28 (41%) patients, at least
once, displayed a decreased ability to degrade NETs
whereas the remaining 41 patients (59%) never displayed
decreased degradation. Out of the 28 patients whose sera
at least once exhibited a decreased ability to degrade
NETs, two had a reduced ability 100% of the times
(13 and 4 time points, respectively), whereas the median
frequency was at 20% (mean 34%) of all time points
(Figure 2C). Together this shows that the ability to
degrade NETs may vary for each patient over time and
also that a decreased ability to degrade NETs is a rather
common feature of SLE and corresponds well to previous
findings [7,8].
The ACR classification criteria for SLE describe cumu-
latively the history of a patient’s clinical manifestations
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Figure 1 Patient SLEDAI-2K decreased during the study. A. Duration of time (in years) during which the patients were included in the study.
Quantiles are shown in gray with a median of 2.1 years (784 days) and mean of 921 days (not shown). B. Individual SLEDAI-2K scores recorded
from patients during the study, divided into intervals of one year from study inclusion. Significance of difference of values compared to the
SLEDAI-2Ks during the first year was calculated using Kruskal-Wallis test followed by Dunn’s post test and is displayed as **, P < 0.01. SLEDAI-2K,
Systemic Lupus Erythematosus Disease Activity Index 2000
Figure 2 Decreased ability to degrade NETs affects 41% of the SLE patients. A-B. The ability of serum to degrade NETs compared to
internal control of serum from 77 healthy controls (A) and 69 patients with SLE followed during multiple time points (B). Dashed line indicates
cut-off for “normal” and “decreased” degradation. C. The fraction of all time points for which patients, who at least once displayed a decreased
ability to degrade NETs, had a decreased NET degrading ability. Quantiles are displayed in gray with a median of 20% and mean of 34% (not
shown). NETs, neutrophil extracellular traps; SLE, systemic lupus erythematosus
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since the onset of disease and give valuable information
of the clinical phenotype. To determine if there was a
certain clinical subgroup of patients who at least once
displayed a decreased ability to degrade NETs compared
to patients who never did, the ACR classification criteria
of the two groups were compared (Table 2). Patients
who at least once exhibited a reduced NET degradation
during the study more often had a clinical history of
antibodies against DNA. These patients with decreased
NET degrading ability also showed an inverse associa-
tion with a history of photosensitivity, a symptom asso-
ciated with a less severe form of SLE.
We also investigated if any particular clinical manifes-
tation, laboratory variable or treatment preceded, co-
occurred or succeeded an episode with decreased NET
degradation. To determine if a decreased degradation of
NETs was associated with these variables that occurred
either two months before sampling, at sampling, or two
months after sampling, the odds ratios (OR) for the dif-
ferent parameters were calculated for sera with a
decreased ability to degrade NETs. The parameters were
divided into three categories; clinical manifestations
derived from SLEDAI-2K, which includes mainly com-
ponents of glomerulonephritis, symptoms from skin, joints
and pleuritis as well as infections (Figure 3A), laboratory
variables (Figure 3B) and medications (Figure 3C). Signifi-
cant associations are also summarized in Table 3.
A decreased ability to degrade NETs was associated with
an increase of one point in SLEDAI-2K score with OR 1.1
(1.0 to 1.2) before sampling, 1.2 (1.1 to 1.3) at sampling
and 1.2 (1.1 to 1.3) after sampling (Figure 3A). A
decreased ability to degrade NETs was further associated
with manifestations that are considered as a part of active
glomerulonephritis consisting of cellular casts, hematuria,
proteinuria, pyuria or all combined with OR 12.8 (2.3 to
67.1) for cellular casts at the time of sampling. The OR for
the presence of proteinuria before, at the time of sampling,
as well as after sampling, were 10.4 (2.49 to 43.9), 8.1 (2.9 to
23.1) and 7.4 (2.1 to 26.6), respectively. When pyuria was
registered, OR was 7.2 (2.0 to 26.0) at the time of sampling
and 5.1 (1.0 to 25.2) after sampling. Additional clinical
manifestations that were not part of glomerulonephritis,
but were associated with a decreased ability to degrade
NETs, were both alopecia and fever with OR 4.8 (1.8 to
12.9) for alopecia and 5.5 (1.4 to 21.3) for fever to develop
two months after an episode with decreased ability to
degrade NETs.
Abnormal levels of some laboratory variables (Figure 3B)
were associated with an increased OR preceding an epi-
sode with decreased ability to degrade NETs. These factors
were elevated anti-DNA antibodies with OR 2.0 (1.2 to
3.5), anti-histone antibodies 2.6 (1.0 to 6.9), the presence
of antibodies against cardiolipin 8.6 (2.0 to 37.1) and ele-
vated CRP 3.1 (1.4 to 6.8). Furthermore, low levels of C3
and leukocytes (leukopenia) also preceded an episode with
decreased degradation with OR 3.0 (1.3 to 7.0) and 5.8
(1.6 to 21.5), respectively. When analyzing laboratory vari-
ables at the same time-point as the episode of decreased
degradation, the following ORs were obtained: anti-DNA
antibodies 1.9 (1.3 to 2.9), anti-histone antibodies 6.6 (2.6
to 16.9) and anti-cardiolipin antibodies 4.1 (1.5 to 14.6).
Reduced complement levels were also associated with an
episode of decreased degradation with OR 2.8 (1.3 to 5.7)
for low C1q, 3.2 (1.6 to 6.5) for low C3 and 3.4 (1.4 to 8.3)
Table 2 ACR classification criteria for patients with normal and decreased ability to degrade NETs
ACR classification criteria Normal
(n = 41)
number (%)
Decreased at least once (n = 28)
number (%)
P-value (Pearson)
Malar rash 27 (66%) 19 (68%) 0.86
Discoid rash 12 (30%) 6 (21%) 0.47
Photosensitivity 30 (73%) 12 (43%) 0.01*
Oral ulcer 8 (20%) 8 (29%) 0.38
Arthritis 32 (78%) 23 (82%) 0.68
Serositis 18 (44%) 17 (61%) 0.17
Nephritis 19 (46%) 16 (57%) 0.38
Neurological disorder 2 (5%) 1 (4%) 0.79
Hematological disorder 21 (51%) 17 (61%) 0.44
Immunological disorder 27 (66%) 26 (93%) 0.009*
Anti-dsDNA 22 (54%) 23 (82%) 0.01*
Anti-Sm 4 (10%) 3 (11%) 0.90
False positive Wasserman 5 (12%) 1 (4%) 0.21
Anti-nuclear antibodies 41 (100%) 28 (100%) -
American College of Rheumatology (ACR) classification criteria reflect the clinical history of systemic lupus erythematosus (SLE) and are compared for patients
who always displayed normal ability to degrade neutrophil extracellular traps (NETs) compared to patients who at least once displayed a decreased ability to
degrade NETs. Asterisks indicate significant differences with the increased proportion highlighted by bold numbers.
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for low levels of C4. Leukopenia also generated an
increased OR of 6.4 (1.9 to 21.6) at the time-point of
decreased degradation of NETs.
Certain medications (Figure 3C) were also more com-
monly administered to patients whose sera had a
decreased ability to degrade NETs. These patients were
more often treated with immunosuppressants both before
and after sampling with OR of 4.5 (1.2 to 16.4) and 5.3
(1.3 to 22.2), respectively. However, no association was
seen at the time of decreased ability to degrade NETs.
Patients on hydroxychloroquine treatment displayed an
inverse correlation with decreased NET-degrading abilities
with an OR of 0.2 (0.05 to 0.5) before, 0.1 (0.04 to 0.4)
after and 0.1 (0.04 to 0.3) at the time of sampling.
Discussion
In the current study we have extensively and in a truly
prospective way, investigated the ability of SLE sera to
Figure 3 Decreased ability to degrade NETs is associated with glomerulonephritis and altered laboratory variables. A-C. Odds ratios for
co-occurrence of indicated parameters in SLE patients with a decreased ability to degrade NETs (n: 26), divided into SLEDAI-2K and clinical
manifestations (A), laboratory variables (B) and medications (C) two months before (red), at the same time (black) or two month after (blue) the
time point with decreased ability to degrade NETs. The odds ratios are indicated with a dot connected to the 95% confidence intervals. All
values that do not cross “1” are considered significant. NETs, neutrophil extracellular traps; SLE, systemic lupus erythematosus; SLEDAI-2K,
Systemic Lupus Erythematosus Disease Activity Index 2000
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degrade NETs with the goal of determining the overall
importance of NET degradation for the disease. This was
done in a longitudinal setup to reveal temporal associa-
tions as well as potential predictive values of the NET
degrading ability. In the present study, 69 patients with
SLE were followed for a median of 784 (mean 921) days
with serum samples collected approximately every 60
days, generating a total of 1,074 measurements. We
found that a decreased ability to degrade NETs was a
rather common feature of SLE with 41% of the patients
at least once, but commonly more than once, displaying
a reduced ability to degrade NETs.
Among the patients that never displayed a reduced abil-
ity to degrade NETs, a clinical history of photosensitivity
was more common whereas the patients who at least once
had a reduced ability to degrade NETs more often dis-
played a clinical history of antibodies against DNA. Based
on the cumulative classification criteria according to ACR,
no other differences could be established between the two
patient groups. ACR classification criteria reflect a cumu-
lative clinical phenotype of SLE but not necessarily the
picture at blood sampling. Therefore, SLEDAI-2K score
was used to evaluate ongoing disease activity at the time
of blood sampling. The cumulative nature of the ACR
classification criteria may also explain why no difference
was observed with a history of glomerulonephritis whereas
active nephritis correlated strongly with a decreased ability
to degrade NETs and has also been established in previous
studies [7,8]. Nephritis in the ACR classification criteria
may reflect events, which occurred long before the study
was initiated and the NET-degrading ability at that time
point is therefore not known. Most patients were included
in the study several years after initial diagnosis.
During the study both the disease activity defined by
SLEDAI-2K score as well as the ability to degrade NETs
improved for most patients. This may be due to the fact
that patients were normally recruited during active disease
and an improvement would hence be expected due to effi-
cient medication. We have previously shown that a
decreased ability to degrade NETs is associated with a
higher SLEDAI-2K score in patients, especially reflecting
patients with nephritis [8], who also normally respond
well to treatment. It is interesting to note that although no
direct efforts were made to restore the ability to degrade
NETs, such improvement was achieved. This indicates
that a reduced ability to degrade NETs may be a secondary
feature of SLE in a stage of active disease. Further, the
results also indicate that regular follow-ups on patients
with SLE may be beneficial in reducing SLE flares.
It has previously been shown that a decreased ability
to degrade NETs is strongly associated with glomerulo-
nephritis and the presence of antibodies directed against
DNA and histones [7,8]. By studying the ability to
degrade NETs in SLE in a longitudinal setting, particular
clinical parameters could be associated with a reduced
NET degrading ability (Table 3). We confirmed that
patients with decreased degradation of NETs more often
suffered from manifestations of glomerulonephritis.
Some manifestations of glomerulonephritis were present
both before and after the time-point with decreased
NET-degradation, whereas cellular casts, as a strong
indication of glomerular damage, only occurred during
the episode with decreased degradation. Interestingly,
alopecia and fever associated strongly only two months
after an episode of decreased NET degradation. This
indicates a predictive value and a potential diagnostic
application but may also give insights into possible con-
sequences of having a reduced ability to degrade NETs
and its overall importance for pathogenesis.
Antibodies against epitopes present on NETs were
further associated with a decreased ability to degrade
NETs. NETs consist of chromatin, including DNA and his-
tones, which are covered with antimicrobial enzymes [6].
Interestingly, elevated levels of antibodies against histone
Table 3 Parameters associated with decreased ability to degrade NETs
approximately 60 days before Simultaneously approximately 60 days after




Laboratory Anti-DNA Anti-DNA Anti-DNA
variables Anti-Histones Anti-Histones Leukopenia
Anti-Cardiolipin Anti-Cardiolipin
Elevated CRP Leukopenia
Low C3 Low C1q, C3 and C4
Medications No HCa No HCa No HCa
Immunosuppressants Immunosuppressants
Manifestations that occur significantly more frequently than expected, before, simultaneously or after the time point with decreased ability to degrade neutrophil
extracellular traps (NETs).
aHC, hydroxychloroquine
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proteins were only associated with reduced ability to
degrade NETs at the same time point as the decreased
degradation occurred. Elevated and high levels (data not
shown) of anti-DNA antibodies were, however, associated
with decreased degradation before, at the same time, as
well as after the episode of reduced degradation. This
implies a more direct effect or response for antibodies
against histones compared to the presence of antibodies
against DNA that may have a slower turnover or response.
Antibodies against DNA are heterogeneous and their
detection varies according to the employed method and
may explain the associations obtained. Notably, elevated
antibody titers against cardiolipin also resulted in an ele-
vated OR for reduced NET degradation both before and at
sampling. The exact mechanisms for this remain to be elu-
cidated since cardiolipin is not a known constituent of
NETs but is, however, present in the cell membrane of
dead cells [20].
Low complement levels are in some cases associated
with disease flare [21] and are also associated with a
decreased ability to degrade NETs. Interestingly, low C3
levels increased the OR for a reduced ability to degrade
NETs within two months. Related to that observation,
elevated levels of CRP also seem to precede an episode
with a reduced ability to degrade NETs. Otherwise, low
C1q and low C4 levels were only associated with
decreased NET degrading ability at the time the
decrease was observed. Patients on hydroxychloroquine
treatment displayed lower ORs for an episode with
reduced ability to degrade NETs. If the antimalarial
therapeutics treatment itself has a direct effect of NET
degradation is an interesting possibility; however, no
effect on NET degradation was observed when hydroxy-
chloroquine was added directly to serum compared to
control (data not shown). The effect is, therefore, most
likely secondary or possibly due to the fact that mainly
patients with less severe form of SLE with mostly symp-
toms from skin and joints, excluding nephritis and pre-
sence of antibodies against DNA, were treated with
hydroxychloroquine.
The frequency of sampling in the study only allows for
detection of associations within two months (46 to 74
days) before or after a measurement and future studies
with more frequent sampling could provide further
details and resolution as in how fast the ability to
degrade NETs changes over time and what parameters
associate with those changes. On the other hand, for the
majority of patients the current frequency proved nar-
row enough since it could take up to half a year to
restore or improve a decreased ability to degrade NETs
for many patients (Figure 2B).
Attempts to treat SLE with DNase-I have been made
since the 1960s, unfortunately problems with antigeni-
city occurred and the trial discontinued [22]. However,
new attempts were initiated with the expression of
recombinant human DNase-I [23], which was also
designed to withstand the presence of potential inhibi-
tors [24]. No clear effects were observed in an early clin-
ical trial in 1999 [23] although animal experiments had
previously shown promising results [25]. Recombinant
DNase-I has, however, been developed as an FDA
approved drug and is used successfully in treating cystic
fibrosis by inhalation [26]. This study reveals in which
SLE patient group the treatment to restore NET degrad-
ing ability may be most beneficial.
Conclusion
The present study confirms previously published results of
manifestations that are directly associated with a decreased
ability to degrade NETs. Further, it expands, for the first
time, on previous findings in a longitudinal setting show-
ing that a decreased ability to degrade NETs is a common
(41% of included patients) feature of SLE. Decreased abil-
ity to degrade NETs is also associated with a history of
anti-DNA antibodies as well as active glomerulonephritis
and high titers of antibodies directed against histone pro-
teins and DNA at the time of decreased degradation.
Additional associations indicate that a reduced ability to
degrade NETs may precede fever and alopecia. Altogether
our findings support the importance of maintaining the
ability to degrade NETs in SLE and may benefit patients
as a diagnostic application.
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